Recent News

• 03.11.2025 - Jefferies Biotech on the Beach Summit
• 03.10.2025 - Leerink Partners 2025 Global Healthcare Conference
• 03.03.2025 - Zai Lab Announces Participation in Investor Conferences in March 2025
• 03.03.2025 - Zai Lab Announces Participation in Investor Conferences in March 2025
• 02.27.2025 - Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
• 02.27.2025 - Zai Lab Full-Year 2024 Financial Results
• 02.19.2025 - Citi - 2025 Virtual Oncology Leadership Summit
• 02.10.2025 - Zai Lab Announces Participation in Investor Conference in January 2025
• 02.10.2025 - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
• 02.10.2025 - Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Recent Filings

• 03.03.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 144 Report of proposed sale of securities
• 02.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.27.2025 - 8-K Current report
• 02.27.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors